News

Aurobindo will shell out $250 million to acquire drugmaker Lannett, shoring up the Indian drugmaker’s footprint in the U.S.
Aurobindo Pharma USA will acquire Lannett from Lannett Seller Holdco for $250 million on a cash-free, debt-free basis.
Nifty Pharma dropped 0.66% at intraday as it underperformed benchmark Nifty 50 which dropped 0.46% at intraday.
Aurobindo Pharma's net profit fell 10.2 per cent Y-o-Y to ₹824 crore in Q1FY26, as against ₹918 crore in the same quarter ...
Recent hiccups related to manufacturing plant issues and tariff uncertainties have led to volatility in earnings and, ...
Elara Capital observes that Aurobindo Pharma has 14 biosimilars in the pipeline. The company has also filed 3 biosimilars for ...
Indian drugmaker Aurobindo Pharma reported a lower first-quarter profit on Monday, as expenses grew faster than revenue - stung by weak prices in the key U.S. market.
ICICI Securities is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1300 in its ...
Prabhudas Lilladher is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1300 in ...
Aurobindo Pharma Ltd. reported a 10.3 per cent year-on-year (YoY) decline in consolidated net profit to Rs 824.2 crore in Q1 ...
Mumbai: Aurobindo Pharma Ltd has posted a 10.2 percent year-on-year (YoY) decline in consolidated net profit for the first ...